Fairmount Funds Management LLC
Profile
- Filings
- 19
- Buy transactions
- 4
- Sell transactions
- 5
- Companies
- 9
- Active
- 2025–2026
Fairmount Funds Management LLC, Director, 10% Owner, has filed 19 SEC reports (2025–2026), spread across 9 companies, totaling $1.3B in disclosed volume. Weighing $53.4M bought versus $1.2B sold, the history is heavily weighted toward selling. The largest single open-market purchase on record is $25.0M in Cogent Biosciences, Inc.. Data is sourced from official SEC Form 3, 4, and 5 filings.
Associated Companies
Spyre Therapeutics, Inc. (SYRE)
2 filings
$400.2M
Cogent Biosciences, Inc. (COGT)
3 filings
$395.0M
$25.0M bought
Oruka Therapeutics, Inc. (ORKA)
3 filings
$305.5M
Apogee Therapeutics, Inc. (APGE)
2 filings
$134.2M
Jade Biosciences, Inc. (JBIO)
2 filings
$12.7M
CRESCENT BIOPHARMA, INC. (CBIO)
2 filings
$12.6M
$12.4M bought
Viridian Therapeutics, Inc.\DE (VRDN)
1 filing
$10.0M
$10.0M bought
Zenas BioPharma, Inc. (ZBIO)
1 filing
$6.0M
$6.0M bought
Damora Therapeutics, Inc. (DMRA)
3 filings
$860.1K
Trading History
| Jul 20 | CBIO CRESCENT BIOPHARMA, INC. | Fairmount Funds Management LLC | Director, 10% Owner | Buy | $12.4M |
| Jul 1 | ORKA Oruka Therapeutics, Inc. | Fairmount Funds Management LLC | Director, 10% Owner | Sell | $300.0M |
| Jun 23 | SYRE Spyre Therapeutics, Inc. | Fairmount Funds Management LLC | Director | Sell | $399.7M |
| Jun 11 | APGE Apogee Therapeutics, Inc. | Fairmount Funds Management LLC | Director | Award | $650.8K |
| Jun 11 | JBIO Jade Biosciences, Inc. | Fairmount Funds Management LLC | Insider | Award | $530.3K |
| Jun 3 | CBIO CRESCENT BIOPHARMA, INC. | Fairmount Funds Management LLC | Director, 10% Owner | Award | $188.0K |
| Jun 3 | ORKA Oruka Therapeutics, Inc. | Fairmount Funds Management LLC | Director, 10% Owner | Award | $504.6K |
| May 29 | SYRE Spyre Therapeutics, Inc. | Fairmount Funds Management LLC | Director | Award | $582.0K |
| Mar 31 | COGT Cogent Biosciences, Inc. | Fairmount Funds Management LLC | Director | Sell | $242.6M |
| Mar 25 | DMRA Damora Therapeutics, Inc. | Fairmount Funds Management LLC | Insider | Award | $860.1K |
| Feb 12 | GLTO Galecto, Inc. | Fairmount Funds Management LLC | Insider | Exercise | $0 |
| Jan 22 | APGE Apogee Therapeutics, Inc. | Fairmount Funds Management LLC | Director | Sell | $133.5M |
| Jan 22 | COGT Cogent Biosciences, Inc. | Fairmount Funds Management LLC | Director | Sell | $127.4M |
| Nov 17 | GLTO Galecto, Inc. | Fairmount Funds Management LLC | Insider | Other | $0 |
| Oct 27 | VRDN Viridian Therapeutics, Inc.\DE | Fairmount Funds Management LLC | Director, 10% Owner | Buy | $10.0M |
| Oct 9 | ZBIO Zenas BioPharma, Inc. | Fairmount Funds Management LLC | Director | Buy | $6.0M |
| Oct 8 | JBIO Jade Biosciences, Inc. | Fairmount Funds Management LLC | Director, 10% Owner | Grant | $12.2M |
| Sep 19 | ORKA Oruka Therapeutics, Inc. | Fairmount Funds Management LLC | Director, 10% Owner | Grant | $5.0M |
| Jul 14 | COGT Cogent Biosciences, Inc. | Fairmount Funds Management LLC | Director | Buy | $25.0M |
19 filings